Nanoengineered photosensitizers for photodynamic priming to overcome P‐glycoprotein‐mediated multidrug resistance
Photochemistry and Photobiology · 2026-03 · 102 (2) · 328-350
DOI: 10.1111/php.70049 ↗At a glance
Journal article in Photochemistry and Photobiology, published online on 2025-11-14. Written by Idrisa Rahman and 7 co-authors. Institution: Fischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA. Major MEDLINE topics: Photosensitizing Agents, Drug Resistance, Multiple, Photochemotherapy, ATP Binding Cassette Transporter, Subfamily B, Member 1. Cited 3 times so far (Crossref); 62 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIH HHS, National Science Foundation, National Institutes of Health.
Abstract (original language)
P‐glycoprotein (P‐gp, ABCB1)‐mediated multidrug resistance (MDR) remains a significant barrier to successful chemotherapy outcomes for cancer patients. While photoactivation of verteporfin (VP), a photosensitizer, has demonstrated success for overcoming MDR through direct protein aggregation upon photoactivation and through adenosine triphosphate (ATP) depletion, the impact of VP's formulation on P‐gp function and cellular energetics has not been fully characterized in this context. In this study, we screened four well‐established VP formulations—liposomal VP (L‐VP), lysophosphatidylcholine‐conjugated VP (lysoPC VP), liposomal formulation of lysoPC VP (L‐lysoPC VP), and a self‐assembled VP nanoaggregate (NanoVP), with a free form of VP as a control—for their ability to inhibit P‐gp. Using a combination of in vitro intracellular VP accumulation assays, P‐gp substrate retention experiments, and Seahorse‐based metabolic profiling, we identified NanoVP as the lead formulation for P‐gp modulation in cancer cells. NanoVP effectively depleted ATP in drug‐resistant cancer cells, while being recognized as a P‐gp substrate. Photodynamic priming with NanoVP at sub‐cytotoxic light doses enhanced P‐gp substrate retention within the cells without damaging P‐gp protein, indicating ATP depletion as the primary mode of functional inhibition. These findings highlighted NanoVP's clinical potential to enhance chemotherapeutic efficacy via photoactivation‐based modulation of P‐gp's function in multidrug‐resistant cancers.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Fischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
- Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID profiles: Anju Meda, Kaitlyn A Moore, Payal Srivastava, Andaleeb Sajid, Suresh V Ambudkar, Huang-Chiao Huang
Funding
- NIH HHS
- National Science Foundation
- National Institutes of Health
Cite
APA
Rahman, I., Meda, A., Moore, K. A., Srivastava, P., Dasgupta, A., Sajid, A., Ambudkar, S. V., & Huang, H. C. (2026). Nanoengineered photosensitizers for photodynamic priming to overcome P‐glycoprotein‐mediated multidrug resistance. Photochemistry and Photobiology, 102(2), 328-350. https://doi.org/10.1111/php.70049
Vancouver
Rahman I, Meda A, Moore KA, Srivastava P, Dasgupta A, Sajid A, et al. Nanoengineered photosensitizers for photodynamic priming to overcome P‐glycoprotein‐mediated multidrug resistance. Photochemistry and Photobiology. 2026;102(2):328-350. doi:10.1111/php.70049
BibTeX
@article{Rahman2026,
author = {Rahman, Idrisa and Meda, Anju and Moore, Kaitlyn A and Srivastava, Payal and Dasgupta, Anika and Sajid, Andaleeb and Ambudkar, Suresh V and Huang, Huang-Chiao},
title = {Nanoengineered photosensitizers for photodynamic priming to overcome P‐glycoprotein‐mediated multidrug resistance},
journal = {Photochemistry and Photobiology},
year = {2026},
volume = {102},
number = {2},
pages = {328--350},
doi = {10.1111/php.70049}
}
EUVIMED